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Background: The present study aimed at using a proteomics based approach to: a) analyze and contrast the
proteome of the healthy and isoproterenol induced hypertrophied hearts and b) identify potential biomarkers for
diagnosis of cardiac hypertrophy.
Methods: Male Sprague Dawley (SD) rats were administered isoproterenol (ISO, 5 mg/kg, sc, once daily) for 14 days
to induce cardiac hypertrophy. There was a significant (p<0.05) increase (~ 55%) in the heart weight to tail length
ratio after 14 days of treatment and cardiac hypertrophy was evidenced by significant increase of β-MHC and ANP,
two indicative markers of cardiac hypertrophy, in the treated heart compared to that of control. Following
confirmation of hypertrophy, 2DE of the tissue samples was done followed by MS/MS analysis of the protein spots
to obtain a proteomic view for identification of novel biomarkers.
Results: Several important proteins were identified by proteomics analysis. They belong to the major functional categories
such as cholesterol and protein metabolism, muscle contraction and development, transport, TCAcycle, ATP-biosynthesis,
chaperone, signal transduction, DNA synthesis and ubiquitinisation. Careful examination of these protein spots by image
analysis led to the successful identification of 7 differentially expressed proteins in the diseased sample. Further extension of
this work for validation of differential expression of these proteins was also achieved by RTPCR and western blotting.
Conclusions: Our results demonstrate characteristic protein expression profile in control and hypertrophy condition in SD
rats and also expand the existing knowledge on differentially expressed proteins in hypertrophy. The study signifies the
importance of reduced expression of a novel protein such as Prohibitin (PHB) which may be associated with the
cardiomyocytes growth and cardiac hypertrophy. However, further work is necessary to confirm the role of PHB in human
heart and its potential role in diagnostic and therapeutic intervention in the clinic.
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Cardiac hypertrophy leading to heart failure is one of
the major causes of morbidity and mortality in the
world. Cardiac hypertrophy is characterized by a chronic
physiological increase in cardiac muscle mass resulting
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distribution, and reproduction in any mediumnormally during development, during pregnancy, and in
response to sustained exercise [1]. However, if this con-
dition persists, although initially compensatory for an
increased workload, prolongation and prevalence of this
process leads to congestive heart failure, arrhythmia, and
sudden death [2]. It may also result from a number of
pathological conditions such as hypertension, valvular
disease, myocardial infarction and cardiomyopathy [3].
At the cellular level, cardiac hypertrophy is character-
ized by an increase in cell size, protein synthesis and re-
activation of the fetal gene program finally leading to
heart failure [4].ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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trophy represents the most widely used model which
mimics the sustained adrenergic stimulation and re-
presents an important hallmark of the pathogenesis of
maladaptive cardiac hypertrophy [5]. The activation of
β-adrenergic signaling in turn induces in the heart many
different mechanisms which contribute to the hyper-
trophic phenotype including enhanced protein synthesis,
proto-oncogene expression, elevated oxidative stress,
stimulation of mitogen activated protein kinases and
phosphotidyl inositol-3 kinases [6]. Studies using trans-
genic mice with heart-specific overexpression of β1-
adrenergic receptors had increased cardiac contractility
at a young age and also developed marked myocyte
hypertrophy. Cardiac hypertrophy was followed by pro-
gressive heart failure with functional deficits similar to
human heart failure [7].
While studies that focus on specific genes or pathways
have provided insights over the years in human and
animal models [8], integrative approaches are equally
important in identifying multiple pathways or novel
markers that are involved in the disease progression and
mechanisms. The changes in protein expression in the
myocardium are critical elements for understanding the
molecular mechanisms of myocardial remodeling or
identifying useful biomarkers for diagnostic purpose
and therapeutic intervention. Two-dimensional gel elec-
trophoresis coupled with mass spectrometry offers a key
advantage of profiling of thousands of proteins in the
biological samples. We therefore aimed to investigate
the alterations in the proteome profile of healthy and
isoproterenol induced hypertrophy in the Sprague–
Dawley rats by proteomics approach using two-
dimensional gel electrophoresis in conjunction with
matrix assisted laser desorption ionization - time of
flight (MALDI-TOF) mass spectrometry to increase our
understanding of the mechanistic pathways involved




The experiments were initiated on 6–7 week old male
Sprague Dawley (SD) rats weighing between 120 –160 g,
obtained from National Institute of Nutrition (NIN), Hy-
derabad, India. The animals were housed in BIOSAFE, an
animal quarantine facility of Indian Institute of Chemical
Technology (IICT, Hyderabad, India), maintained at a
temperature of 22 ± 2°C and relative humidity of 50±15%.
Animals were acclimatized for a period of one week before
the start of the study. A 12 hour dark/light cycle
was maintained throughout the study. Air changes
(15–16 cycles/hr) were maintained with 5 μ HEPA filter.
Rats had free access to food (pellet diet supplied fromNational Institute of Nutrition, Hyderabad) and water
ad libitum. The study protocols followed were in ac-
cordance with the guidelines of the Institutional Animal
Ethics Committee of Indian Institute of Chemical Tech-
nology, Hyderabad and conform with the Guide for the
Care and Use of Laboratory Animals published by the
US National Institutes of Health (NIH Publication No.
85–23, revised 1985). For the development of hyper-
trophy all animals were weighed, and randomly divided
into two groups: Control (Con: saline administration
through subcutaneous route, 14 days, n=8) and Hyper-
trophy (Hyp: isoproterenol administration through sub-
cutaneous route, 5 mg/kg/day, 14 days, n= 8) [9]. Food
and water intake was recorded daily. Body weight was
taken at the start and end of 14 days. After sacrificing
the rats, the heart tissues were carefully isolated and ex-
cised. Then hearts were washed three times with 1X
PBS (pH-7.4) and stored in −80°C freezer for future use.
Estimation of heart weight/tail length ratio
In each group, heart weight/tail length ratio was mea-
sured on the day of sacrifice as a parameter of cardiac
hypertrophy. Tail length was measured by using a centi-
meter (cm) scale. Heart weight (gm) was measured after
keeping the heart in ice cold saline and blotting out the
heart with tissue paper [10].
β-MHC and ANP gene expression as markers of cardiac
hypertrophy
Total RNA (DNAase free) was isolated from heart tissues
using TRI REAGENT (Sigma, St. Louis, MO, USA). Re-
verse transcription was performed by using the MMLV
reverse transcriptase kit (M6125H, Epicenter, WI, USA)
for first-strand cDNA synthesis [11]. Real-time PCR was
performed by using SYBR® Green PCR Master Mix (2X)
(Takara, Takara Bio. Inc., Japan) and following gene spe-
cific primers: forward primer, 5′-AGAGCAAAAGCAAA
GGGTTTC-3′ and reverse primer, 5′-GTGATGGTAC
GAGATGGGCTA-3′ for β-MHC and forward primer,
5′- AGCGAGCAGACCGATGAAG-3′ and reverse primer,
5′-AGCCCTCAGTTTGCTTTTCA-3′ for ANP. PCR
amplification of RPL32 (16S Ribosomal protein L32)
cDNA was performed as reference control by using the
following primer pair: forward primer, 5′-AGATTCAAG
GGCCAGATCCT -3′ and reverse primer, 5′-CGATGGC
TTTTCGGTTCTTA-3′.
Protein extraction and quantitation
Approximately 80 mg of the heart tissue of control and
cardiac hypertrophy samples were homogenized in a ratio
of 1:20 with RIPA buffer in an electrical homogenizer
followed by sonication with sonicator. The samples were
then centrifuged at 14,000 rpm for 30 min at 4°C. The
supernatant was collected and precipitated by standard
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solubilized in a sample buffer (8.0 M urea, 2% CHAPS,
50 mM DTT) at 4°C. The protein concentration of these
protein extracts was determined using the Bradford pro-
tein assay kit (Biorad, Hercules, CA, USA) according to
the manufacturer’s instructions using BSA as a standard.
This protein sample could be used for 2-DE or stored in
−70°C until used. Biolyte 3/10 ampholytes (0.2%) and
bromophenol blue (trace) were added to the protein sam-
ple prior to 2-DE (rehydration).
One dimensional gel electrophoresis (1-DE)
One dimensional SDS-PAGE was initially performed for
preliminary proteomic profiling of control and hyper-
trophic heart samples according to Laemmli [12].
Two dimensional gel electrophoresis (2-DE)
Protein samples (200 μg) were applied to an immobilized
pH gradient (IPG) strip (7 cm, pH 4–7, Linear) (BioRad,
Hercules, CA, USA) using a passive rehydration method
(16 h of rehydration at 20°C) according to the manufac-
turer’s instructions. The IPG strips were then transferred
to an isoelectric focusing (IEF) cell (BioRad, Hercules, CA,
USA) and IEF was performed on a 7cm gel strip according
to the manufacturer’s instructions. Prior to second dimen-
sion, the gel strips were equilibrated for 15 min twice in
equilibration buffers I and II as previously described. The
second dimension was performed using 12% SDS-PAGE at
80 V. The gels were stained using the fast-coomassie stain-
ing method and scanned with a BioRad GS-800scanner. At
least two independent runs were performed for each sam-
ple to ensure the accuracy of analyses. The 2D gel maps
were analysed by the ‘Progenesis same spots software’
(Non-linear dynamics, Durham, NC, USA). The quantity
of each spot in a gel was normalized as a percentage of the
total quantity of all spots in that gel and evaluated in terms
of optical density (OD). Only spots that showed consistent
and significant differences were selected for MS analysis.
In-gel trypsin digestion
In-gel digestion of proteins was carried out using MS-grade
Trypsin Gold (Promega, Madison, WI, USA) according to
the manufacturer’s instructions. Spots were cut out of the
gel (1–2 mm diameter) using capillaries, and destained
twice with 25 mM NH4HCO3/50% acetonitrile (ACN) at
room temperature for 45 min in each treatment. This was
followed by dehydration of the gels with 100% ACN for
5 min. After dehydration and drying, the gels were pre-
incubated in 10–20 μl trypsin solution (20 ng/μl) for 1 h.
Then samples were added in adequate digestion buffer
(25 mM NH4HCO3/50% ACN) to cover the gels and incu-
bated overnight at 37°C. Tryptic digests (peptides) were
extracted twice with 50% ACN/5% trifluoroacetic acid
(TFA) for 30 min each time. The combined extracts weredried in a vacuum concentrator at room temperature. The
extracted peptides were dissolved in 2.5 μl of 50% ACN/
0.1% TFA, and then 0.8 μl of the digests was mixed with
0.8 μl of 5 mg/ml alpha-cyano-4-hydroxy-cinnamic acid
(CHCA) (Applied Biosystems, Framingham, MA) in 50%
ACN/0.1% TFA and spotted onto a MALDI target plate.
Mass spectrometry (MALDI-TOF analysis)
The samples were analyzed on a 4800 Proteomics
Analyzer MALDI-TOF/TOF mass spectrometer (Applied
Biosystems, Framingham, MA) working in positive ion re-
flector mode. Peptide mass fingerprint (PMF) of the
tryptic digests was acquired in an automation mode. MS/
MS was performed in a data-dependent mode in which
the top ten most abundant ions for each MS scan were
selected for MS/MS analysis. The MS/MS data were ac-
quired and processed using the global proteomics software
and MASCOT was used to search the database. This soft-
ware creates a peaklist from the raw spectra with a given
threshold after removal of trypsin, polymer peaks, noise
peaks and subjected to database interrogation for protein
identification.
Protein identification
PMF data was interrogated for protein identification with
NCBI database for Rattus using the mascot search engine
(www.matrixscience.com). Searches were performed with-
out constraining protein molecular weight or isoelectric
point, with complete carbamidomethylation of cysteine,
partial oxidation of methionine residues, and 1 missed
cleavage was also allowed in the search parameters. Pro-
teins with probability-based Molecular Weight Search
(MOWSE) scores exceeding their threshold (P<0.05),
number of matched ions, number of matching ions with
independent MS/MS matches, percent protein sequence
coverage, and correlation of gel region with predicted
MW and pI were collectively considered for each protein
identification. The peptide and fragment mass tolerance
were set at 100 ppm, respectively.
RNA isolation and Reverse Transcriptase PCR (RTPCR)
Total RNA was isolated and Reverse transcriptase-
polymerase chain reaction(s) were performed as described
earlier in section 2.3. PCR was performed by using dNTPs
Taq DNA polymerase, MgCl2 and specific primers
according to the manufacturer’s instructions (Takara Taq
kit, Takara Bio. Inc., Japan). The primers for RTPCR ana-
lysis (Table 1) were designed using Primer 3 software
(from published sequence information), avoiding regions
of homology with other genes, for the following genes:
MYL-2, MYL-3, PEBP-1, PHB, HSP60, ATP5β and
Desmin. The PCR product was separated on a 2% agarose
gel stained with ethidiumbromide. The gel images were
captured using gel documentation system and
Table 1 List of primer sequences for gene of interest
Gene of interest Primers Sequence Tm
MYL2 Forward primer 5'-GAAAGCCAAGAAGAGGTTAGAGG-3' 55°C
Reverse primer 5'-ATGGTGAGGAACACAGTGAAGTT-3'
MYL3 Forward primer 5'-AAGAGCTCAACTCCAAGATGATG-3' 55°C
Reverse primer 5'-TCTCTACCTCGTCTTCTGTCAGC-3'
PEBP1 Forward primer 5'-GTCATGAATAGACCAAGCAGCAT-3' 57°C
Reverse primer 5'-CTCATACACCAGCCAGACGTAG-3'
PHB Forward primer 5'-GGGTACAGAAGCCAATCATCTTT-3' 55°C
Reverse primer 5'-AATGCTGGTGTAGATACGAGGAA-3'
HSP60 Forward primer 5'-GCAGAGTTCCTCAGAGGTTGG-3' 53°C
Reverse primer 5'-CCCAGCAGCATCCAGTAAAG-3'
Atp5b Forward primer 5'-TGTATTTGCTGGTGTTGGTGA-3' 53°C
Reverse primer 5'-ACCTTGGAAGTGGCATCTTTT-3'
Desmin Forward primer 5'-CTGATAGACGACCTGCAGAGG-3' 55°C
Reverse primer 5'-AAGGAATGCAATCTCCTCGTT-3'
GAPDH Forward primer 5'-TGGTGCTCAGTGTAGCCCAG-3' 58°C
Reverse primer 5'-GGACCTGACCTGCCGTCTAG-3'
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Software (NIH, Bethesda, MD, USA). For quantitative
analysis, the signal intensity of each band was normalized
with the GAPDH signals.
Immunoblot analysis
Total protein extraction and immunoblotting was
performed as described previously [13]. Protein concen-
tration was determined by Bradford method (Bio-Rad,
Hercules, CA, USA). An equal amount (20 μg) of protein
of each of the samples under study was separated by so-
dium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS–PAGE). After electrophoresis, protein was trans-
ferred to PVDF membranes (GE Healthcare, USA). The
membranes were then blocked in Tris-buffered saline
Tween-20 (TBS-T; 10 mM Tris, pH 7.5, 150 mM NaCl,
0.05% Tween-20) and 5% non-fat dry milk for 1 h, and
subsequently washed and incubated with primary anti-
bodies in TBST with 2.5% non-fat dry milk at 4°C for
overnight. The following polyclonal antibodies and titres
were used: MYL2 (1:20,000, LS BioScience #LSc105679),
MYL3 (1 μg/ml, LS BioScience # LSc107502), PEBP1
(0.02 μg/ml, LS BioScience # LSb3247), PHB (2 μg/ml, LS
BioScience # LSc29731), Hsp60 (1:300, Abbiotec #250700),
ATPase 5β (1:500, LS BioScience # LS- C137091) and β-
actin (1:1000, abcam #ab8224). After washing with TBS-T,
membranes were incubated with Goat Anti-Rabbit IgG–
HRP (1:1500 dilution, Santa Cruz Biotechnology, # SC
2004) or Goat Anti-Mouse IgG-HRP (1:1500 dilution, Santa
Cruz, #2005) horseradish peroxidase conjugated secondary
antibody with 2.5% non-fat dry milk at room temperaturefor 1 h. After washing with TBS-T immunoreactions were
visualized with a chemiluminescence detection kit (Prod
No- 34080, Super signal® west Pico chemiluminescent sub-
strate, Thermo Scientific). Then the blots were exposed to
X- ray film (Hyperfilm ECL, GE Healthcare, USA) and de-
veloped by using a hyper processor (Model -SRX -101A,
Amershan Biosciences). Gel stained with coomassie blue
served as an equal loading control. Quantification of band
intensity was performed using the Image J Software (NIH,
Bethesda, MD, USA). For quantitative analysis, the signal
intensity of each of the protein was normalized with the
corresponding β-actin signal.Statistical analysis
All values were expressed as mean ± SEM. Data were
statistically analyzed using student unpaired ‘t’ test for
group wise comparison. Significance was set at P≤0.05.Results
Development of hypertrophy in SD rats
Isoproterenol (5 mg/kg/day) was administered through
subcutaneous route for 14 days to induce cardiac hyper-
trophy. There was 55% increase in heart weight and tail
length ratio observed in hypertrophy (Hyp) group com-
pared to control (Con) group (Figure 1A & B). The mRNA
levels of hypertrophic marker, β-MHC and ANP were an-
alyzed by Real time PCR which showed elevated levels
of this mRNA in Hyp heart compared to Con heart





























































Figure 1 Chronic administration of isoproterenol caused
cardiac hypertrophy in SD rats. (A) Images of whole heart from
control and isoproterenol-treated SD rat. (B) Heart weight and tail
length ratio from control and isoproterenol-treated SD rat. (C) β-
MHC gene expression from both control and hypertrophic heart
measured by Real-time PCR. (D) ANP gene expression from both
control and hypertrophic heart measured by Real-time PCR. Data
shown as mean ± SEM, * p ≤0.05 versus control.
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Using the above hypertrophy data as guide, we proceeded
to examine the global protein complement of left ven-
tricular muscle isolated from control and hypertrophied
heart to identify the proteins exhibiting altered abundance
as a function of disease progression. For preliminary com-
parison of the expression levels of total protein extracted
from the left ventricle of control and hypertrophy heart
samples, we performed one dimensional gel electropho-
resis. Additional file 1 (Additional material) shows the
representative 1-DE gel image of proteins isolated from
cardiac tissue of control and hypertrophic SD rats
(Additional file 1: Figure S1). However, since each band in
1D can be a mixture of one, two or more proteins, the re-
sults of MALDI-TOF MS analysis indicated protein
identification with low MOWSE scores (data not shown).
Therefore, to further improve the resolution of separation
and identification of differentially expressed proteins in
control and hypertrophic samples we carried out two di-
mensional gel electrophoresis. Proteins (200 μg) extracted
and estimated as described in materials and methods for
the chosen samples, were separated in the first dimension
by isoelectric focusing on strip gel with pI range 3–10 and
in the second dimension using 12.0% SDS–PAGE followed
by Fast coomassie staining method. 2-DE of the samples
on a 3–10 pI IPG strip indicated better resolution of pro-
teins in the pI range of 4–7 and therefore 2DE was carried
out using IPG strips with pI 4–7. The protein profile of
control and hypertrophic heart was compared. The pro-
tein spots which were differentially expressed in both the
samples are indicated in Figure 2. These bands were
picked up and digested by in-gel trypsin digestion. This
was followed by identification with MALDI-TOF MS. The
peptides mass peaks were compared with those in the
NCBI database (Figure 3).
The functional cardiac proteome
We initially focused on identifying the proteins of the
cardiac proteome from the control sample. The condi-
tions used for profiling 2-D gel allowed access to a total
of ~60 visible proteins. All these spots were marked in
the control sample and in-gel trypsin digestions followed
by mass spectrometry were performed for subsequent
identification. Figure 2 shows the representative 2-D gel





































Figure 2 2-DE gel analysis of proteins extracted from the cardiac tissue of SD rats. In the first dimension, 200 μg of protein was loaded on
a 7 cm IPG strip with a linear gradient of pH 4–7. In the second dimension, 12% SDS –PAGE gels were used. Proteins were visualized by fast
coomassie staining. All the differentially expressed spots were marked and identified by MS-analysis. Sizes of the molecular mass markers (in KDa)
are indicated.

































List  of some of the matched peptides






Figure 3 MALDI-TOF mass spectra of the prohibitin protein isolated from the 2D gels of protein extracts of cardiac tissue. Some of the
matched peptides are labelled bold on the peaks.
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Table 2 List of proteins identified from 2D gels of protein extracts of cardiac tissue





1. Uncharacterised gi|55628 Unnamed protein product [rattus norvegicus] 14 75 70670 6.09
2. Transport gi|149033753 Albumin, isoform cra_a [rattus norvegicus] 13 78 53060 6.72
3. Transport gi|149033753 Albumin, isoform cra_a [rattus norvegicus] 10 87 53060 6.72
4. Chaperone gi|1000439 +gi|
178847300
grp75 [rattus sp.] chain a, crystal structure of the
70-kda heat shock cognate protein
31 110 73984 5.87
+59895 5.91
5. Uncharacterised gi|149041392 rcg57965, isoform cra_b 9 65 48623 6.16
6. Signal transduction gi|149022678 Mitogen activated protein kinase 8 interacting
protein, isoform cra_d
6 47 75419 4.73
7. Chaperone gi|1000439 grp75 [rattus sp.] 10 72 73984 5.87
8. Muscle contraction and
development
gi|149058891 Calpastatin, isoform cra_a 4 43 20886 5.20
9. Uncharacterised gi|1334284 Unnamed protein product 8 47 58061 5.35
10. Chaperone gi|56383 Heat shock protein (hsp60) precursor 17 90 61098 5.91
11. Uncharacterised gi|1334284, Unnamed protein product 13 74 58061 5.35
12. Muscle contraction and
development
gi|11968118 Desmin 7 61 53481 5.21
13. Muscle contraction and
development
gi|11968118 Desmin [rattus norvegicus] 29 226 53481 5.21
14. ATP biosynthesis gi|1374715 ATP synthase beta subunit 32 159 51171 4.92
15. ATP biosynthesis gi|1374715 ATP synthase beta subunit 22 140 51171 4.92
16. Uncharacterised gi|293344961 predicted: hypothetical protein 7 45 32379 8.55
17. TCA cycle gi|149025181 Dihydrolipoamide s-succinyltransferase
(e2 component of 2-oxo-glutarate comp.
7 55 21198 6.92
18. TCA cycle gi|149025181 Dihydrolipoamide s-succinyltransferase
(e2 component of 2-oxo-glutarate comp.
5 55 21198 6.92
19. Transport gi|149033753 Albumin, isoform cra_a 13 87 53060 6.72
20. Transport gi|149033753 Albumin, isoform cra_a 14 83 53060 6.72
21. Transport gi|149033753 Albumin, isoform cra_a 13 82 53060 6.72
22. Transport gi|149033753 Albumin, isoform cra_a 13 78 53060 6.72
23. Uncharacterised gi|149066551 rcg59557 5 54 12861 9.18
24. Uncharacterised gi|149063941 rcg23467, isoform cra_a 5 51 223560 5.59
25. Muscle contraction and
development
gi|6981240, Myosin light chain 3 16 97 22256 5.03
26. Muscle contraction and
development
gi|6981240, Myosin light chain 3 13 55 22256 5.03
27. Protein, cholesterol
metabolism
gi|149063506 Phosphatidylethanolamine binding protein 1,
isoform cra_a
7 42 10775 6.26
28. Protein, cholesterol
metabolism, transport
gi|6978515 Apolipoprotein a-i preproprotein 3 43 30100 5.52
29. DNA synthesis gi|6679299 Prohibitin 5 141 29859 5.57
30. Uncharacterised gi|149054764 rcg33654, isoform cra_d 14 48 16329 5.45
31. Ubiquitinisation gi|149016294 F-box only protein 36 (predicted), isoform cra_c 4 40 9895 9.52
32. Muscle contraction and
development
gi|127167 Myosin regulatory light chain 2, ventricular/
cardiac muscle isoform
6 120 18868 4.86
33. Muscle contraction and
development
mlrv_rat mlrv_rat, myosin regulatory light chain 2,
ventricular/cardiac muscle isoform
12 169 18868 4.86
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Table 2 List of proteins identified from 2D gels of protein extracts of cardiac tissue (Continued)
34. Uncharacterised gi|293349387 Predicted: hcg2036631-like 23 54 51880 9.69
35. Protein,cholesterol
metabolism
gi|149043202 Calpain 9 7 43 51956 5.79
36. Transport gi|13162363 Fatty acid-binding protein, heart 9 96 14766 5.91
37. Muscle contraction and
development
gi|20302069 Heat shock protein beta-6 9 68 17551 6.05
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cated. A total of 37 proteins were identified (Additional
file 2: Figure S2 & Table 2) with significant score. The
functional classification of the identified proteins resulted
in the following major categories: Cholesterol and protein
metabolism, muscle contraction and development, trans-
port, TCA cycle, ATP-biosysnthesis, chaperone, signal
transduction, DNA synthesis and ubiquitinisation. Figure 4A
shows the pie chart grouping of the identified proteins into
functional classes annotated using the expasy database
(http://expasy.org/uniprot). Figure 4B shows the pie chart
grouping of the identified proteins based on their cellular
localization.
Comparative proteome profiling of control and
hypertrophic heart tissues
In an effort to gain insight into the molecular mecha-
nisms underlying the pathogenesis of cardiac hyper-
trophy, we also performed a comparative analysis of the
protein expression profiles of control and cardiac hyper-
trophy samples of rats by image analysis of 2D gels using
‘progenesis same spots software’. This resulted in the
identification of several differentially expressed protein
spots between control and cardiac hypertrophy gels.
These differentially expressed proteins of cardiac hy-
pertrophy are shown in Figure 5 and listed in Table 2.
These include fatty acid binding protein, heart (H-FABP)
(spot no. 36), phophatidylethanolamine binding protein
(PEBP1) (spot no. 27), apolipoprotein A-1 preprotein
(spot no.28), calpain 9 (spot no.35), heat shock cognate
protein, 70 kda (HSP70) (spot no.4), heat shock protein
60 precursor (HSP60) (spot no. 10) and heat shock pro-
tein B6 (HSPB6) (spot no.37), mitogen activated protein
kinase 8 interacting protein (isoform CRA-d) (spot no.6),
myosin light chain 3 (MYL3) (spot no.24,25), myosin light
chain 2 (MYL2) (spot no. 32,33), desmin (spot no.12,13),
dihydrolipoamide succinyltransferase (spot no.18), F-box
only protein 36 (isoform CRA_c) (spot no. 31), ATP syn-
thase β-subunit (ATP5β) (spot no.14,15) and prohibitin
(PHB) (spot no. 29) (Figure 5).
Gene expression analysis for the validation of proteomics
data
We attempted further validation of seven differentially
expressed proteins by semiquantitative RTPCR to checkthe mRNA expression levels at the transcriptional level
(Figure 6). There was a significant (p<0.05) decrease in
levels of MYL2, MYL3, PEBP1, PHB and ATP5β gene
levels in hypertrophy (Hyp) group compared to control
(Con). Although, there was an increase in HSP60 and
decrease in Desmin gene expression levels observed
in the hypertrophy (Hyp) group compared to Control
(Con), these changes were not significant. GAPDH was
used as an internal control for normalization in the gene
expression studies.
Immunoblot analysis for the validation of the
proteomics data
Immunoblot analysis was performed for these differen-
tially expressed proteins with specific antibodies to vali-
date the levels obtained from 2-DE data. β- actin was
used as a reference for comparison of protein levels.
There was no change in HSP60 expression observed in
hypertrophy (Hyp) group compared to control (con).
However, significant decrease in protein levels was ob-
served for MYL2, ATP5β and PHB compared to control
(Figure 7). Although there was a decrease in protein
levels for both MYL3 and PEBP1 in Hyp group com-
pared to Con but it was not significant.
Discussion
Several attempts have been tried on cardiac tissues to
disclose underlying molecular pathogenesis of cardiac
hypertrophy in different disease models [14]. However,
there is no proteomic study to identify important targets
or biomarkers from isoproterenol-induced hypertrophy
heart. To the best of our knowledge, this study consider-
ably resolves the proteome of healthy and diseased
hearts to investigate and understand the complex mech-
anism of isoproterenol induced cardiac hypertrophy.
Table 2 provides a summary of the list of proteins identi-
fied from the 2D gels of cardiac tissue of SD rats. By this
approach we were also able to identify several proteins
which were specifically and significantly altered in car-
diac hypertrophy.
In the present study, we demonstrate that isoproterenol
induced cardiac hypertrophy effects at the molecular level,
affecting the cardiac protein expression profiles in SD rats.
The protein(s) of the following functional categories are
altered, the expression of which were further validated by




























Classification of the identified proteins based on  
their localization
Figure 4 Classification of identified proteins based on their function and cellular localization. (A) Pie chart grouping the identified















Figure 5 Close up areas of the gels showing variation in the intensity of the differentially expressed protein spots among the control and
the hypertrophic SD rats. For ease of comparision, spots are indicated by circle. Control is used as a reference for comparision. The identity of the
proteins is as follows: A. gi|11968118 desmin; B. gi|56383 heat shock protein (hsp60) precursor; C. gi|1374715 ATP synthase beta subunit; D,E. rCG41226;
isoform CRA_b [Rattus norvegicus] rCG59557; F,G. gi|149063941, rCG23467, isoform CRA_a, gi|6981240, myosin light chain 3; H,I,J. gi|149063506,
phosphatidylethanolamine binding protein 1, isoform CRA_a, gi|6978515, apolipoprotein A-I preproprotein gi|6679299, prohibitin; K. gi|149016294,
F-box only protein 36 (predicted), isoform CRA_c; L. gi|20302069 Heat shock protein beta-6; M,N. gi|127167 Myosin regulatory light chain 2, ventricular/
cardiac muscle isoform, gi|127167 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform; O. gi|149043202, calpain 9 (nCL-4);
P. gi|13162363, fatty acid-binding protein, heart.













































Figure 6 Gene expression analysis by RTPCR. (A) Gene expression of MYL3, MYL2, HSP60, PEBP1, PHB, ATP5β and Desmin in control and
hypertrophy heart. GAPDH is loading control for RTPCR. (B) Densitometry analysis (relative density against GAPDH) of all genes obtained by
RTPCR. Data shown as mean ± SEM, * p ≤0.05; **P≤0.005; ***P≤0.0005 versus control.
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development, (ii) Transport, (iii) Chaperones, (iv) ATP
biosynthesis, (v) DNA synthesis. An intriguing question
which rises following this study is whether this differential
protein expression analysis might reveal some novel plaus-
ible candidates which could act as master regulators
responsible for hypertrophy. Identification of novel target
is critical to develop new class of drug molecules to
modulate or alter the protein function in hypertrophy.
Therefore, we initially provide details of proteins which
were differentially expressed in our study of isoproterenol-
induced hypertrophy and the expression of which are in
consistence with the prior studies in other models (such
as endothelin-1(ET-1) or leukemic inhibitory factor (LIF)
induced hypertrophy models or other models of heart
failure, strokes, myocardial infarction MI(s) etc.), followed
by detailed description of protein prohibitin, which we
speculate as a novel potential biomarker in isoproterenol-
induced hypertrophy.
Concerning the category (i), we observed a reduction in
MYL2 and MYL3 protein levels in isoproterenol-induced
hypertrophy compared to control indicating cardiacdamage. Myosin light chain 2 (MYL2), also known as my-
osin regulatory light chain is implicated in myosin ATPase
activity and smooth muscle contraction. Mutations in
MYL2 are well associated with familial cardiac hyper-
trophy [15]. Similarly, MYL3 is associated with cardiac mi-
crofibrillar assembly and heart contraction [16]. Changes
in the levels of myosin light chain 2 and myosin light
chain 3 (MYL2 and MYL3) proteins upon isoproterenol
treatment, observed in our study are consistent with the
earlier observations of heart failure or cardiomyopathy
[17]. Down regulation of MYL2 was observed in human
heart failure tissues and this data suggested that MYL2
may play a role in the development and progression of
chronic heart failure [18]. Serum proteomic signature
of human chagasic patients, (caused by infection with
trypanosoma cruzi) where there is a decline in heart func-
tion, revealed decrease in MYL 2 levels [19]. Desmin is
another protein of category I, which along with other pro-
teins acts as a major stress bearing element in the sarco-
mere. The levels of this protein are reported to increase
along with other cytoskeletal proteins such as tubulin,


























MYL3/ -actin MYL2/ -actin HSP60/ -actin PEBP1/ -actin PHB/ -actin ATP5   / -actin
Control
Hypertrophy
Figure 7 Protein expression analysis by immunoblots. (A) Protein expression of MYL3, MYL2, HSP60, PEBP1, ATP5β and PHB in control and
hypertrophy heart. β- actin is used as a loading control for immunoblot analysis. (B) Densitometry analysis (relative density against β- actin) of all
proteins obtained by immunoblots. Data shown as mean ± SEM, * p ≤0.05 versus control.
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from compensated ventricular hypertrophy to heart failure
[21]. However, in contrast to other studies we observed a
decrease in desmin gene expression levels in isoproterenol-
induced hypertrophy. This might be due to different type of
cardiac hypertrophy model and early stages of heart failure.
Category (ii) includes transport proteins such as fatty
acid binding protein, Heart (H-FABP), which interestingly
showed decrease in the levels in the hypertrophic heart in
our 2D gels. H-FABP is known to be involved in fatty acid
beta oxidation, intracellular utilization of fatty acids and
long chain fatty acid transporter activity. It has been earlier
reported as a serum marker for the early diagnosis of stroke
as well as acute and chronic myocardial infarctions. H-
FABP levels are significantly elevated above their threshold
level within 3hrs of myocardial infarction and subsequently
return to normal levels within 12-24 hrs [22]. However cor-
onary ligation (MI and ramipril treatment) decreased the
protein expression of H-FABP in the left ventricular tissue
compared to sham group. In addition, ramipril (known for
beneficial role in cardiovascular diseases) treatment caused
an increase in H-FABP of rabbit LV with MI indicating thatramipril may modulate the expression of H-FABP by post
translational modifications [23].
The Heat shock proteins (HSP60, HSP70 and HSPD1),
representing category (iii) increased in the isoproterenol-
induced disease model in comparison to control in the
present study. Interestingly, these proteins are known to
change in abundance during cardiac hypertrophy in vitro
and have also been shown to change in human/animal
models of hypertrophy [24]. Proteomic analysis revealed
significant elevation of heat shock protein 70 in patients
with chronic heart failure due to arrhythmogenic right
ventricular cardiomyopathy (ARVC). Results of the study
indicated that elevated HSP70 levels as the common
feature of heart failure due to ARVC, DCM, and ICM
suggesting that HSP70 may be used as a biomarker for the
presence of heart failure due to cardiomyopathies of
different etiologies and may hold diagnostic/prognostic
potential in clinical practice [25]. Also, proteomic analysis
in congestive heart failure revealed significant alternations
of cardiac small heat shock protein expression [26].
Concerning the effect of Isoproterenol on ATP biosyn-
thesis (category IV), the energetics of hypertrophy (LV)
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failure, abnormalities are found in myocardium relating
to substrate use, oxidative phosphorylation, and the high
energy transfer mechanism involving creatine. Consisent
with this we observed a decrease in ATP-synthase 5β
levels in hypertrophic heart compared to control heart.
However, cardioprotection against hypobaric hypoxia
showed elevated levels of ATP-synthase 5β suggesting
improvement in mitochondrial energy metabolism [27].
In the present study, we identified prohibitin, a mito-
chondrial protein, as differentially expressed and decreased
significantly in hypertrophic heart compared to control
(Figure 5 and Figure 6). Prohibitins are ubiquitous, evo-
lutionarily conserved proteins that are mainly localized in
mitochondria [28]. Although the accumulating evidence
suggests that prohibitins are localised primarily within
mitochondria, their function remains poorly understood.
Studies in different organisms have provided significant
insights into the role of the prohibitin complex in mito-
chondrial biogenesis and metabolism [29]. Mitochondrial
dysfunction is believed to be involved in the process of free
radical generation, leading to hypertrophy and heart failure
[30]. Isoproterenol-induced cardiac injury is associated
with mitochondrial disorder affecting one or more of the
respiratory redox chain [31]. The heart tissues, which rely
most extensively on aerobic metabolism, are most severely
affected by mitochondrial defects. Therefore, attention has
been recently focused towards investigation of mitochon-
drial function and its biogenesis.
To our knowledge, this study provides the first expe-
rimental evidence for decreasing levels of prohibitin
(PHB) expression in hypertrophic rat heart. The expre-
ssion of PHB1 is also down-regulated after induction of
oxidative stress in epithelial cells as well as in diseases
linked to enhanced reactive oxygen species (ROS) such
as ulcerative colitis and Crohn’s disease [32] Oxidative
stress has been identified as one of the key contributing
factors in the progression and development of cardiac
hypertrophy. Several research articles support the fact
that ROS generated from mitochondria cause cardiac
hypertrophy [9]. Although increased ROS and mitochon-
drial dysfunction are associated with cardiac hypertrophy,
it is not known if PHB is able to collectively control these
events or have an impact on cardiac hypertrophy. Knock-
down of prohibitin (PHB1) in endothelial cells increases
mitochondrial production of reactive oxygen species via
inhibition of complex I [33]. It is possible that decreased
expression of PHB in hypertrophy heart might be respon-
sible for mitochondrial dysfunction and oxidative stress.
Evidence of increased oxidative stress in isoproterenol-
induced cardiac hypertrophy was reported earlier [34].
Therefore, we hypothesize that the reduced expression of
PHB might be responsible for mitochondrial dysfunction
and increased oxidative stress in isoproterenol-inducedcardiac hypertrophy. Future treatment strategy can be initi-
ated to increase mitochondrial PHB by pharmacological
and/or therapeutic agents. Alternatively, PHB can also be
used as a potential biomarker for stress induced cardiac
hypertrophy.
Conclusions
The successful use of multiple techniques, including 2-DE
and MALDI-TOF-MS demonstrates that proteomic ana-
lysis provides appropriate means for identifying cardiac
biomarkers in hypertrophy. The analysis of changes in
myocardial protein expression may serve as source of
possible biomarkers for hypertrophic cardiac damage. Our
data offer new insights into understanding the cellular and
molecular mechanisms that underlie cardiac dysfunction
in cardiac hypertrophy induced by “a catecholamine”. The
present study identifies alteration in the prohibitin levels,
as a key actor and contributor to the progression of
cardiac hypertrophy and heart failure. Data obtained in
experimental animals must be extrapolated to the clinical
arena for further investigation. Nevertheless, the findings
from the present study show that prohibitin could be use-
ful to predict the therapeutic response to established and
novel therapies for the prophylaxis of cardiac hypertrophy
and subsequent heart failure in cardiac patients.
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hypertrophic heart. Approx 20 μg of protein from control (C1, C2, C3)
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Additional file 2: Figure S2. Protein profiling of the control and
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were separated on 2D PAGE and visualized by fast coomassie staining.
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by MS-analysis.
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